Evidence map›Paper›PMID 41857315›Full record

ReviewMolecular biomedicine2026

The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets.

Yilin Hong, Hanshi Guo, Qiang Chen, Chundong Yu

Abstract readReview
In one paragraph

Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yilin Hong *Xiamen Key Laboratory of Traditional Chinese Medicine Bio-Engineering, School of Pharmacy, Xiamen Medical College, Xiamen, Fujian, 361023, China.
Hanshi Guo *State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, 361104, China.
Qiang ChenDepartment of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Health Science Center, Ningbo University, Ningbo, Zhejiang, 315211, China. chenqiang1@nbu.edu.cn.
Chundong YuState Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian, 361104, China. cdyu@xmu.edu.cn.ORCID http://orcid.org/0000-0002-4141-8345

Funding

National Natural Science Foundation of China 82303144National Natural Science Foundation of China 82371764National Natural Science Foundation of China 82503151Natural Science Foundation of Fujian Province 2025J08328Natural Science Foundation of Ningbo Municipality 2023J375Natural Science Foundation of Xiamen Municipality 3502Z202571070Zhejiang Provincial Natural Science Foundation of China LQ24H160002
6 · The paper itself

Abstract

The Jumonji C domain-containing (JMJD) family of histone demethylases constitutes an essential class of epigenetic regulators that dynamically sculpt gene expression programs through the erasure of methyl groups from histone lysine and arginine residues. Dysregulation of these enzymes is increasingly implicated in the pathogenesis of a wide spectrum of human diseases. Yet, a fragmented, disease-specific understanding has thus far hindered a unified view of their functions across different pathological states. In this review, we provide a comprehensive and comparative analysis of the JMJD family, synthesizing their roles and mechanisms across diverse human conditions, including cancer, neurological disorders, inflammatory, autoimmune, cardiovascular, and metabolic diseases. We highlight that individual JMJD proteins can function paradoxically as both promoters and suppressors of pathology, a duality determined by the specific cellular and pathological context. A key novelty of our work is its integrated, cross-disease perspective, which moves beyond conventional silos to illuminate common pathophysiological pathways and unique regulatory networks orchestrated by these epigenetic erasers. Furthermore, we critically assess the associated therapeutic landscape, summarizing advances in the development of small-molecule JMJD inhibitors and discussing innovative strategies to tackle enduring challenges, such as enzymatic redundancy and selectivity. By integrating insights from disparate disease models, this review seeks to forge a holistic understanding of JMJD biology and accelerate the development of novel epigenetic therapeutics directed at this pivotal protein family.

Indexed as

Jumonji Domain-Containing Histone DemethylasesAnimalsEnzyme InhibitorsEpigenesis, GeneticHistonesHumansMolecular Targeted TherapyEnzyme InhibitorsHistonesJumonji Domain-Containing Histone DemethylasesDisease pathogenesisEpigeneticHistone demethylasesJMJD familyJMJD inhibitors

Identifiers

PMID41857315
PMCPMC13003115

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.